Lucy Scientific Discovery Past Earnings Performance
Past criteria checks 0/6
Lucy Scientific Discovery's earnings have been declining at an average annual rate of -26.7%, while the Pharmaceuticals industry saw earnings growing at 0.03% annually.
Key information
-26.7%
Earnings growth rate
10.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | -12,605.2% |
| Net Margin | -61,141.1% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Lucy Scientific Discovery makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -10 | 7 | 0 |
| 30 Sep 23 | 0 | -10 | 6 | 0 |
| 30 Jun 23 | 0 | -9 | 6 | 0 |
| 31 Mar 23 | 0 | -7 | 4 | 0 |
| 31 Dec 22 | 0 | -5 | 3 | 0 |
| 30 Sep 22 | 0 | -6 | 4 | 0 |
| 30 Jun 22 | 0 | -6 | 3 | 0 |
| 31 Mar 22 | 0 | -7 | 4 | 0 |
| 31 Dec 21 | 0 | -7 | 4 | 0 |
| 30 Sep 21 | 0 | -6 | 3 | 0 |
| 30 Jun 21 | 0 | -5 | 3 | 0 |
Quality Earnings: LSDI is currently unprofitable.
Growing Profit Margin: LSDI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LSDI is unprofitable, and losses have increased over the past 5 years at a rate of 26.7% per year.
Accelerating Growth: Unable to compare LSDI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LSDI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.5%).
Return on Equity
High ROE: LSDI has a negative Return on Equity (-12605.21%), as it is currently unprofitable.